Holen Sie sich die Stockscreener-App
1.045
0.48%
0.005
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CTXR?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$1.04
Offen:
$1.04
24-Stunden-Volumen:
133.09K
Relative Volume:
0.17
Marktkapitalisierung:
$19.30M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-39.14M
KGV:
-0.175
EPS:
-5.97
Netto-Cashflow:
$-28.20M
1W Leistung:
-9.91%
1M Leistung:
-2.34%
6M Leistung:
+14.51%
1J Leistung:
-59.65%
1-Tages-Spanne:
$1.03
$1.096
1-Wochen-Bereich:
$1.03
$1.1957
52-Wochen-Spanne:
$0.65
$5.95
Citius Pharmaceuticals Inc Stock (CTXR) Company Profile
Firmenname
Citius Pharmaceuticals Inc
Sektor
Branche
Telefon
(908) 967-6676
Adresse
11 COMMERCE DRIVE, CRANFORD, NJ
Vergleichen Sie CTXR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CTXR
Citius Pharmaceuticals Inc
|
1.045 | 19.21M | 0 | -39.14M | -28.20M | -5.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
447.57 | 114.05B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
748.17 | 78.80B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.32 | 53.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.76 | 51.80B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
164.42 | 42.33B | 447.02M | -1.18B | -906.14M | -6.1812 |
Citius Pharmaceuticals Inc Stock (CTXR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-30 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2021-11-30 | Eingeleitet | Maxim Group | Buy |
Citius Pharmaceuticals Inc Aktie (CTXR) Neueste Nachrichten
Can Citius Pharmaceuticals Inc. stock resist market sell offsJuly 2025 Macro Moves & Safe Entry Trade Reports - Улправда
Citius Oncology closes $18 million in offerings to support LYMPHIR launch - Investing.com Nigeria
Citius Oncology Announces Closing of $18 Million Concurrent Regi - GuruFocus
Citius Oncology closes $18 million in offerings to support LYMPHIR launch By Investing.com - Investing.com South Africa
Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Barchart.com
Citius Oncology shares sink after announcing $18M fundraising deal - MSN
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules - Sahm
Aug Selloffs: Is Citius Pharmaceuticals Inc stock positioned for digital transformationPortfolio Gains Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
Is Citius Pharmaceuticals Inc. (47N0) stock good for wealth creationJuly 2025 Momentum & Safe Investment Capital Preservation Plans - Newser
How Citius Pharmaceuticals Inc. (47N0) stock reacts to fiscal policiesJuly 2025 Big Picture & Trade Opportunity Analysis - Newser
CTXR: Analyst Jason Kolbert Maintains 'Buy' Rating with $6 Price Target | CTXR Stock News - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim - The Malaysian Reserve
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Midd - GuruFocus
Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim – Company AnnouncementFT.com - Financial Times
How supply shortages influence Citius Pharmaceuticals Inc. (47N0) stockWeekly Market Outlook & AI Powered Trade Plan Recommendations - Newser
How Citius Pharmaceuticals Inc. (47N0) stock responds to bond market2025 Investor Takeaways & AI Enhanced Trading Signals - Newser
Cutaneous T-cell Lymphoma Market Expected to Experience Major Growth by 2032, According to DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG, oligenix, Ligand - Barchart.com
Citius Oncology launches Lymphir treatment for rare lymphoma - NJBIZ
How Citius Pharmaceuticals Inc. (47N0) stock reacts to new regulations2025 Analyst Calls & Momentum Based Trading Signals - Newser
Is Citius Pharmaceuticals Inc. (47N0) stock vulnerable to rate hikesDollar Strength & Capital Efficiency Focused Ideas - Newser
Citius Oncology enters distribution services agreement with Cardinal Health - MSN
Why Citius Pharmaceuticals Inc. (47N0) stock is a must watch tickerWeekly Loss Report & Reliable Entry Point Trade Alerts - Newser
Citius Oncology Launches LYMPHIR, The First CTCL Systemic Therapy In Over 7 Years - Nasdaq
Citius Pharmaceuticals Launches LYMPHIR for T-Cell Lymphoma - MSN
Will Citius Pharmaceuticals Inc. (47N0) stock boost dividends furtherProduct Launch & Stepwise Trade Signal Implementation - Newser
How Citius Pharmaceuticals Inc. (47N0) stock moves in volatile trading sessions - Newser
Citius Oncology Announces U.S. Commercial Launch of LYMPHIRtm, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Lelezard
CTORCitius Oncology, Inc. Latest Stock News & Market Updates - Stock Titan
Citius Pharmaceuticals, Inc. Launches LYMPHIR for CTCL Treatment - TradingView — Track All Markets
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Finviz
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) – Company AnnouncementFT.com - Financial Times
Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL) - Sahm
Citius Oncology (Nasdaq: CTOR) debuts LYMPHIR in over $400 million U.S. CTCL market - Stock Titan
Why Citius Pharmaceuticals Inc. stock remains resilientIPO Watch & AI Forecasted Entry/Exit Points - BỘ NỘI VỤ
Citius Oncology Deploys AI Platform to Amplify the Performance of its Commercial Team Ahead of LYMPHIR Launch - Aktiellt
Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting - 富途牛牛
Citius Oncology (NASDAQ: CTOR) to Exhibit LYMPHIR for CTCL Patients at ASH 2025 - Stock Titan
Butterfly Network, Citius Pharma Drive Biotech Momentum In After-Hours Trading - Nasdaq
Citius Oncology to advance LYMPHIR launch with AI technology By Investing.com - Investing.com Nigeria
Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration - Placera.se
Citius Oncology stock soars on expanded AI collaboration for LYMPHIR launch - Investing.com
Citius Oncology to advance LYMPHIR launch with AI technology - Investing.com India
Citius Oncology (Nasdaq: CTOR) taps Verix AI to support Q4 2025 LYMPHIR CTCL launch - Stock Titan
Can Citius Pharmaceuticals Inc. (47N0) stock sustain free cash flow - newser.com
How Citius Pharmaceuticals Inc. stock reacts to Fed rate cutsStop Loss & Weekly High Potential Stock Alerts - newser.com
Can Citius Pharmaceuticals Inc. (47N0) stock withstand sector downturns2025 Top Decliners & Long-Term Safe Investment Plans - newser.com
Is Citius Pharmaceuticals Inc. (47N0) stock good for long term investingMarket Activity Summary & Daily Entry Point Trade Alerts - newser.com
Finanzdaten der Citius Pharmaceuticals Inc-Aktie (CTXR)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.21%
0.15%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):